Physician profile
Michael M Radin
NPI 1407812449
$7,368.22
in general payments reported to CMS, 2019-2025
37 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,521 · 2020: $645 · 2021: $1,305 · 2022: $833 · 2023: $705 · 2024: $826 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,490.13 | 2019-2025 | Watchman Flx |
| Amgen INC. | $763.25 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $758.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $527.84 | 2020-2025 | Farxiga, Fasenra |
| Amarin Pharma, INC. | $507.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $479.45 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $397.41 | 2019-2023 | Xarelto |
| Biotronik INC. | $314.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.40 | 2019-2025 | Jardiance |
| Philips North America LLC | $223.08 | 2020-2025 | (9280) Lm Accessories, Extended Holter |
| Regeneron Healthcare Solutions, INC. | $204.13 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $188.34 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $175.40 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $151.88 | 2024-2025 | Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $133.93 | 2020-2025 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $126.63 | 2022-2024 | Optimizer, Optimizer |
| Scpharmaceuticals INC. | $119.10 | 2023-2025 | |
| Pfizer INC. | $114.19 | 2021-2024 | |
| Astellas Pharma US INC | $83.12 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $76.24 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $47.07 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $35.80 | 2019 | |
| Azurity Pharmaceuticals, INC. | $32.72 | 2025 | Edarbyclor, Edarbi |
| Kowa Pharmaceuticals America, INC. | $31.69 | 2019-2020 | |
| Abbott Laboratories | $31.05 | 2021-2022 | |
| Lilly USA, LLC | $28.36 | 2025 | Mounjaro, Zepbound |
| Janssen Scientific Affairs, LLC | $28.36 | 2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $19.82 | 2025 | Assure Wcd |
| Lundbeck LLC | $18.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.87 | 2020 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Radin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.